3rd International Congress on Biomedicine (ICB2019)
Bevacizumab in treatment of glioblastoma
Bevacizumab in treatment of glioblastoma
Saeed Abedian,1,*Rasul Saberi,2Sahar Jouybar,3
1. Islamic Azad University of shahrood 2. Islamic Azad University of Mashhad 3. Varstegan Institue for Medical Science
Introduction: Glioblastoma is one of the most deadly and vascularized malignancies of primary neoplasm of the brain, therefore anti-angiogenic therapy is a superior method for the treatment of glioblastoma. Bevacizumab (Avastin) is a monoclonal antibody that neutralizes vascular epithelial factor, which was approved by the FDA in 2009 for the treatment of ricarent glioblastoma. The aim of this study is to evaluate the efficacy of acetone alone or in combination with other methods to improve glioblastoma.
Methods: By entering keywords and applying Title / Abstract filter on Pubmed database in Articles 2014 to 2019, 40 articles were found, of which 11 were related to the target topic. Also on the Google Scholar database by searching for articles in 2019, 15 topics were relevant to the subject. And in the Sciencedirect database, searching for articles in the last 5 years, 7 articles were extracted and finally 33 articles were used to study.
Results: Bevacizumab is an active ingredient of avastin which is a human recombinant monoclonal IgG1 antibody (93% human, 7% murine sequences - molecular weight 149 kDa). And is produced using DNA technology that selectively binds to all vascular endothelial growth factor (VEGF) isoforms and prevents binding to VEGFR-1, VEGFR-2 receptors by spatial deformation. This drug in the treatment of glioblastoma improves peripheral edema and reduces tumor blood supply and reduces VEGF overexpression in glioblastoma however, bevacizumab alone gives 3/3 months progression-free survival (PFS) at average. However, it does not have a significant effect on overall survival (OS). Also, bevacizumab co-administration with conventional and routine glioblastoma treatment (radiotherapy and temozolamide) has little effect on increasing PFS and OS in patients. Overall, bevacizumab can increase PFS duration in patients but has no significant effect on OS. The most common side effects of bevacizumab are hypertension and proteinuria, which are 23% and 2.2% of patients, respectively. However, most of the side effects of bevacizumab are due to the glioblastoma process itself.
Conclusion: Although bevacizumab has no acceptable effect on PFS and OS, it can be effective in the treatment of glioblastoma due to its positive effects such as decreased tumor blood supply, decreased VEGF expression and increased PFS duration.